These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35255355)

  • 1. Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.
    Malinga NZ; Siwele SC; Steel HC; Kwofie LLI; Meyer PWA; Smit T; Anderson R; Rapoport BL; Kgokolo MCM
    Transl Oncol; 2022 May; 19():101384. PubMed ID: 35255355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
    Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
    Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.
    Kgokolo MCM; Anderson K; Siwele SC; Steel HC; Kwofie LLI; Sathekge MM; Meyer PWA; Rapoport BL; Anderson R
    Front Oncol; 2022; 12():819790. PubMed ID: 35223501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
    Rapoport BL; Steel HC; Hlatshwayo N; Theron AJ; Meyer PWA; Nayler S; Benn CA; Smit T; Kwofie LLI; Heyman L; Anderson R
    Front Immunol; 2022; 13():823842. PubMed ID: 35677046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy.
    Labuschagne Naidoo RB; Steel HC; Theron AJ; Anderson R; Tintinger GR; Rossouw TM
    Pathogens; 2024 Jun; 13(7):. PubMed ID: 39057767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
    Mahmoudian RA; Mozhgani S; Abbaszadegan MR; Mokhlessi L; Montazer M; Gholamin M
    J Mol Histol; 2021 Jun; 52(3):597-609. PubMed ID: 33884540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.
    Kgokolo MCM; Malinga NZ; Steel HC; Meyer PWA; Smit T; Anderson R; Rapoport BL
    Transl Oncol; 2024 Apr; 42():101867. PubMed ID: 38308919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 9. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
    Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases.
    Cai X; Zhan H; Ye Y; Yang J; Zhang M; Li J; Zhuang Y
    Front Genet; 2021; 12():785153. PubMed ID: 34917131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
    Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
    Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma.
    Zou WQ; Luo WJ; Feng YF; Liu F; Liang SB; Fang XL; Liang YL; Liu N; Wang YQ; Mao YP
    Front Immunol; 2022; 13():818411. PubMed ID: 35140722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Immune Cell Checkpoints during Sepsis.
    Patil NK; Guo Y; Luan L; Sherwood ER
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29135922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.